STOCKS TELEGRAPH

Author: Asim Kamal

  • Here is why Vislink Technologies Inc. (VISL) stock performed well on Monday?

    Here is why Vislink Technologies Inc. (VISL) stock performed well on Monday?

    Vislink Technologies Inc. (VISL) shares surged 4.37% in after-hours on Monday, November 15, 2021, and closed the Monday trading at $1.91. Even in the regular trading session, VISL’s stock gained 2.81%. VISL shares have risen 61.95% over the last 12 months, and they have moved up 7.02% in the past week. Over the past three months, the stock has lost 3.17%, while over the past six months, it has declined 18.30%.

    Let’s discuss its recent news and developments.

    VISL latest news

    On November 15, 2021, Vislink (VISL) reported financial results for the quarter that ended September 30, 2021.

    Q3 2021 financial highlights

    • VISL reported revenue of $11.2 million for Q3 2021, compared to $4.8 million for Q3 2020. For Q2, 2021 revenue was $7.6 million.
    • In Q3 2021, the gross margin was 62.3% compared to 31.8% of revenue in the third quarter of 2020. The gross margin was 52.8% in Q2 2021.
    • Total operating expenses were $11.7 million in Q3 2021 compared to $7.6 million in Q3 2020.
    • It earned a net income of $676,000, or $0.01 per share in the third quarter of 2021 compared to a net loss of $2.8 million, or $0.17 per share in the third quarter of 2020.
    • As of September 30, 2021, Vislink had $38 million in cash.

    VISL launched Vislink Connect

    On October 18, 2021, Vislink (VISL), launched Vislink Connect™, a premium bonded cellular service designed to enable robust, reliable and economical transmissions for live video production. The service is available to U.S customers for pre-ordering immediately.

    Vislink rapidly merged the operations of the recently acquired Mobile Viewpoint. The company focus was the integration of their respective product lines through advanced interoperability testing and other shared engineering initiatives. Vislink Connect is the first jointly-developed product offering brought to market by the combined companies.

    VISL participation at CABSAT 2021 event

    On October 06, 2021, Vislink (VISL) and Mobile Viewpoint exhibited in person at this year’s CABSAT 2021 event, which took place on October 26-28, 2021, at the Dubai World Trade Centre. The company displayed its products at two locations on the show floor. The products displayed were HCAM, which is the most widely deployed HEVC 4K UHD wireless transmitter. Quantum is an IP-native, high-performance RF receiver that enables production teams to fully implement remote production systems to increase efficiencies and many other products were also showcased during the event.

    Conclusion

    The recent improved financial results were the reason behind its positive performance on the first day of the week and we can expect it to perform well in the coming trading sessions on Tuesday.

     

     

  • Why did Dyne Therapeutics Inc. (DYN) stock soar on Friday?

    Why did Dyne Therapeutics Inc. (DYN) stock soar on Friday?

    Dyne Therapeutics Inc. (DYN) shares surged 8.97% in the after-hours on Friday and closed the weekly trading at $15.55. In the regular trading session of Friday, DYN’s stock gained 0.42% as well. DYN shares have fallen 28.44% over the last 12 months, and they have moved down 4.99% in the past week. Over the past three months, the stock has lost 13.83%, while over the past six months, it has shed 20.63%.

    Let’s see what is the latest news about the company?

    DYN latest announcement

    On November 04, 2021, Dyne Therapeutics, Inc. (DYN) reported financial results for the third quarter of 2021.

    Q3 2021 financial highlights

    • DYN reported no revenue in Q3 2021.
    • Research and development expenses were $36.5 million in Q3 2021 compared to $9.7 million in the third quarter of 2020.
    • General and administrative expenses were $6.3 million during the third quarter of 2021, compared to $3.8 million for the third quarter of 2020.
    • It suffered a net loss of $42.6 million or $0.83 per share of common stock for the third quarter of 2021 compared to $13.9 million, or $2.01 per share of common stock for the third quarter of 2020.
    • Dyne ended the quarter with $407.5 million of cash, cash equivalents, and marketable securities, which are anticipated to fund operations into the second half of 2024.

    DYN hosted the first R&D Day

    On October 13, 2021, Dyne Therapeutics, Inc. (DYN), hosted its first Research and Development Day highlighting Company’s co-lead development programs for rare muscle diseases, Duchenne muscular dystrophy (DMD), and myotonic dystrophy type 1 (DM1).

    DYN participation at 2021 Muscle Study Group Annual Scientific Meeting 

    Dyne Therapeutics, Inc. (DYN), presented new data during the 2021 Muscle Study Group Annual Scientific Meeting for its Duchenne muscular dystrophy (DMD) program that shows robust and durable exon skipping and dystrophin expression in both cardiac and skeletal muscles in vivo models.

    These new data build on previous results in the MDX model showing treatment with FORCE resulted in enhanced functional benefit in multiple standardized assessments and a reduction in serum creatinine kinase, a biomarker of muscle damage.

    Conclusion

    We have no reason to justify its good performance on Friday. we hope that it will continue to perform well after the weekend as well.

    About the company

    Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases.

     

  • Why did Harmony Biosciences Holdings Inc. (HRMY) stock surge on Friday?

    Why did Harmony Biosciences Holdings Inc. (HRMY) stock surge on Friday?

    Harmony Biosciences Holdings Inc. (HRMY) shares surged 12.34% in after-hours on Friday, November 12, 2021, and closed the weekly trading at $47.78. in the regular trading session, HRMY’s stock gained 0.02%. HRMY shares have fallen 3.21% over the last 12 months, and they have moved up 1.36% in the past week. Over the past three months, the stock has gained 34.97%, while over the past six months, it has soared 42.38%.

    Let’s have a brief discussion about its recent news and developments.

    HRMY participation in the upcoming investor conferences

    Harmony Biosciences Holdings, Inc. (HRMY) will participate at Jefferies London Healthcare Conference and Piper Sandler 33rd Annual Virtual Healthcare Conference. Harmony’s President and CEO, John C. Jacobs, will participate in fireside chats and host investor meetings during both events.

    HRMY latest financial results

    On November 09, 2021, Harmony Biosciences Holdings, Inc. (HRMY) reported financial results for the quarter ended September 30, 2021.

    Q3 2021 financial highlights

    • HRMY reported total revenue of $80.7 million Q3 2021 compared to $45.6 million for the same period in 2020.
    • The cost of revenue was $66.12 million in Q3 2021, compared to $37.7 million in Q3 2020.
    • Total operating expenses were $45.1 million in the third quarter of 2021 as compared with $27.3 million for the same quarter in 2020.
    • It suffered a GAAP net loss of was $9.6 million, or a loss of $0.17 per diluted share in Q3 2021 compared to a net loss of $4.1 million, or a loss of $0.14 per diluted share in Q3 2020.
    • Harmony ended the quarter with cash and cash equivalents of $189.7 million.

    HRMY added to S&P SmallCap 600® Index

    Harmony Biosciences Holdings, Inc. (HRMY), was added to the S&P SmallCap 600® Index on Friday, October 22, 2021.

    At this moment, President and Chief Executive Officer of Harmony, John C. Jacobs, said that he is very pleased that Harmony was included in the S&P SmallCap 600® Index and is proud of this recognition. He further said that the inclusion in the index will increase our visibility and raise awareness of the work we are doing to help patients, as we continue to build a leading rare neurological disease company.

    Update about HRMY WAKIX® (pitolisant)

    On September 2, 2021, the American Academy of Sleep Medicine (AASM) published an updated clinical practice guideline, which includes Harmony Biosciences Holdings, Inc. (HRMY) WAKIX® (pitolisant) as a recommended treatment option for adults living with narcolepsy.

    The new clinical practice guideline was published in the Journal of Clinical Sleep Medicine in a special.

    WAKIX, a first-in-class medication, is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy and has been commercially available in the U.S. since Q4 2019.

    Conclusion

    Well, as of this writing, there is no recent news which could be the reason behind its positive performance on Friday. let’s see how it performs on Monday after the weekend?

  • Here is why International Tower Hill Mines Ltd. (THM) face headwinds in the after-hours on Friday?

    International Tower Hill Mines Ltd. (THM) shares plunged 7.97% in after-hours on Friday, November 12, 2021, and closed the weekly trading at $0.87. However, in the regular trading session of Friday, THM’s stock gained 24.00%. THM shares have fallen 38.57% over the last 12 months, and they have moved up 32.38% in the past week. Over the past three months, the stock has gained 10.56%, while over the past six months, it has declined9.62%.

    Let’s have a brief look at its recent news and developments.

    THM latest news

    On November 12, 2021, International Tower Hill Mines Ltd. (THM) filed its unaudited third-quarter Financial Statements for the three and nine-month period ended September 30, 2021.

    Q3 2021 financial highlights

    • There was no revenue generated by the company during Q3 2021.
    • Total operating expenses were $1.90 million in Q3 2021 compared to $1.18 million in Q3 2020.
    • It suffered a net loss of $1.65 million in Q3 2021 compared to a net loss of $1.1 million in Q3 2020.
    • As of September 30, 2021, the company had cash and cash equivalents of $9.3 million.

    THM PFS of Livengood Gold Project

    On November 4, 2021, International Tower Hill Mines Ltd. (THM) announced the results of the Pre-Feasibility Study for its Livengood Gold Project located near Fairbanks, Alaska.

    According to the report, the project w would process 65,000 tons per day and produce 6.4 million ounces of gold over 21 years from a gold resource estimated at 13.6 million ounces at 0.60 g/tonne.

    The PFS estimated the capital costs of the Project at US$1.93 billion, the total cost per ton milled at US$13.12, and the all-in sustaining costs at US$1,171 per ounce. The PFS estimated a 5% NPV of US$400 million at $1,800/oz US$975 million at US$2,000/oz, and US$2.3 billion at $US2,500/oz.

    Conclusion

    As the company is still not generating any revenue from its Livengood Gold Project located along the paved Elliott Highway, 70 miles north of Fairbanks, Alaska, therefore its stock price went down in the after-hours after its Q3 2021 financial results announcement.

    Let’s see how it performs in the coming trading session after the weekend?

     

  • Why did Vicinity Motor Corp. (VEV) Stock turn around towards negativity in the after-hours on Friday?

    Why did Vicinity Motor Corp. (VEV) Stock turn around towards negativity in the after-hours on Friday?

    Vicinity Motor Corp. (VEV) shares plunged 6.64% in after-hours on Friday, November 12, 2021, and closed the weekly trading at $3.94. However, in the regular trading session of Friday, VEV’s stock gained 3.94%. VEV shares have risen 68.77% over the last 12 months, and they have moved up by 1.69%. Over the past three months, the stock has lost 22.57%, while over the past six months, it has declined 19.92%.

    Let’s have a brief look at its recent news.

    VEV latest development

    On November 12, 2021, Vicinity Motor Corp. (VEV) announced its financial and operational results for the third quarter of 2021.

    Q3 2021 financial highlights

    • VEV reported total revenue of $2.9 million in Q3 2021 compared to $8.9 million in Q3 2020.
    • In Q3 2021, gross profit was negative $0.7 million compared to a gross profit of $0.6 million in the same year-ago quarter.
    • It suffered a net loss of $4.8 million, or $0.16 per share, compared to a net loss of $1.3 million, or $0.05 per share in Q3 2020.
    • Adjusted EBITDA was negative $3.5 million in Q3 2021 compared to an adjusted EBITDA loss of $0.7 million in Q3 2020.
    • As of September 30, 2021, the company had cash, and cash equivalents totaling $5.0 million.

    FY 2022 financial outlook

    Vicinity Motor expects revenue of $140 million and an adjusted EBITDA of at least $10 million for FY 2022.

    VEV new appointment

    On November 2, 2021, Vicinity Motor Corp. (VEV) appointed respected commercial transportation veteran Brent Phillips as Senior Director of Sales, North America, to lead the Company’s sales activities throughout the U.S. and Canada.

    Brent has over 20 years of experience in the commercial transportation field, with a specific focus on commercial buses and trucks and previous leadership roles at the distribution and manufacturing level, including sales, marketing, and operations.

    VEV 100 VMC 1200 truck LOI from Pioneer Auto Group

    On November 1, 2021, Vicinity Motor Corp. (VEV) received a letter of intent from Pioneer Auto Group for 100 VMC 1200 Class 3 Electric Trucks worth approximately CAD 14 million.

    The Founder and CEO of Vicinity Motor Corp, William Trainer, said that Pioneer is a well-known and highly rated auto dealer with 17 locations across British Columbia, making them an excellent strategic partner to introduce our new Vicinity 1200 medium-duty electric truck throughout the province.

    VEV participation at APTA’s TRANSform Conference & EXPO

    Vicinity Motor Corp. (VEV) participated and showcased its vehicles at the APTA’s TRANSform Conference & EXPO which took place on November 8-10 in Orlando, Florida at the Orange County Convention Center.

    Conclusion

    The recent Q3 2021 financial results were the reason behind its loss in the after-hours on Friday. Let’s see how it commences trading on Monday?

  • Rover Group Inc. (ROVR) Stock went down in the after-hours on Friday, But Why?

    Rover Group Inc. (ROVR) Stock went down in the after-hours on Friday, But Why?

    Rover Group Inc. (ROVR) shares declined 5.29% in after-hours on Friday, November 12, 2021, and closed the weekly trading at $13.08. However, in the regular trading session of Friday, ROVR’s stock gained 5.66%. The stock volume remained 0.33 million shares. ROVR shares have moved up by 14.04% in the past week. Over the past three months, the stock has gained 41.06%, while over the past six months, it has surged 39.92%.

    Let’s see, is there any recent news behind its after-hours loss on Friday?

    ROVR confidential proposed public offering

    On November 09, 2021, Rover Group, Inc. (ROVR) confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of its Class A common stock. All the shares will be sold by stockholders of Rover that were investors in A Place for Rover, Inc, before its merger with Nebula Caravel Acquisition Corp. Rover will not receive any proceeds from the sale of Class A common stock.

    ROVR latest financial results

    On November 08, 2021, Rover Group, Inc. (ROVR), announced financial results for the third quarter ended September 30, 2021.

    Q3 2021 financial highlights

    • ROVR reported total revenue of $35.2 million in Q3 2021, compared to $13.3 million in Q3 2020.
    • Total cost and expenses were $34.4 million in Q3 2021 compared to $20.6 million in Q3 2020.
    • The company suffered a GAAP net loss of $84.5 million in Q3 2021 compared to a net loss of $10.4 million in Q3 2020.
    • Adjusted EBITDA was $6.6 million in Q3 2021 compared to $1.18 million in Q3 2020.

    FY 2021 financial outlook

    For FY 2021, Rover is expecting,

    • Total revenue in the range of $106million to $110 million.
    • Adjusted EBITDA in the range of $6million to $9 million.

    ROVR participation in the recent investor conference

    Rover Group, Inc. (ROVR) management participated in a fireside chat at the Morgan Stanley Annual Spark Conference, which was held on October 13, 2021.

    ROVR best dog companies list

    On September 28, 2021, Rover.com® (ROVR), released its Best Dog-Friendly Companies 2021 report, which ranks the top workplaces across the U.S. in their dog-friendly cultures. All the companies listed in the report maintained, and in many cases strengthened, their commitment to providing their employees with dog-friendly benefits.

    According to Rover, the top three best companies are Amazon, Athena health, LLC, and Trupanion.

    Conclusion

    Well, there was no reason behind its plummeting in the after-hours on Friday. We hope that it will return to positivity after the weekend.

     

  • Why did Xeris Biopharma Holdings Inc. (XERS) Stock have a good Friday?

    Xeris Biopharma Holdings Inc. (XERS) shares jumped 7.01% in after-hours on Friday, November 12, 2021, and closed the weekly trading at $2.29. Even in the regular trading session of Friday, XERS’s stock gained 2.88%. XERS shares have fallen 59.00% over the last 12 months, and they have moved up 9.74% in the past week. Over the past three months, the stock has lost 3.60%, while over the past six months, it has declined 38.51%.

    Let’s discuss its recent news and developments.

    XERS recent financial results

    On November 10, 2021, Xeris Biopharma Holdings, Inc. (XERS), reported financial results for the third quarter, and the first nine months ended on September 30, 2021.

    Q3 2021 financial highlights

    • XERS reported total net sales of $11.03 million in Q3 2021 compared to $9.4 million in Q3 2020.
    • The cost of goods sold was $3.2 million in Q3 2021, compared to $2.8 million in Q3 2020.
    • Research and development expenses were $5.7 million in Q3 2021 compared to $3.9 million in Q3 2020.
    • Selling, general and administrative expenses were $26.5 million in Q3 2021 compared to $16.5 million in Q3 2020.
    • Xeris suffered a net loss of $26.0 million, or $0.39 per share in Q3 2021, compared to a net loss of $16.0 million or $0.35 per share in Q3 2020.
    • The company ended the quarter with total cash, cash equivalents, and investments of $93.0 million, compared to $133.8 million on December 31, 2020.

    XERS collaboration with Merck

    On October 25, 2021, Xeris Biopharma Holdings, Inc. (XERS), announced a collaboration agreement with Merck.

    According to the agreement, Merck will get licensed Xeris’ suspension-based formulation technology, XeriJect™, for use with undisclosed monoclonal antibodies (mAbs) for engineering ultra-high concentration, ready-to-use formulations. The terms of the agreement were not disclosed.

    XERS completed Strongbridge Biopharma acquisition

    On October 05, 2021, Xeris Pharmaceuticals, Inc. (XERS) completed the previously announced acquisition of Strongbridge Biopharma plc (SBBP).

    Both companies combined under Xeris Biopharma Holdings and shares of Xeris Biopharma Holdings began trading on the Nasdaq under the ticker symbol “XERS” from October 6, 2021.

    XERS inducement grants

    On October 01, 2021, the Compensation Committee of Xeris Pharmaceuticals, Inc. (XERS), granted restricted stock units for an aggregate of 28,750 shares of its common stock to 20 new employees under Xeris’ Inducement Equity Plan.

    Conclusion

    Well, as of this writing there is no recent news or development which could justify its good performance on Friday. we hope that it will commence the trading in a positive mode after the weekend as well.

     

     

  • Here is why Creative Realities Inc. (CREX) stock skyrocketed in the after-hours on Friday?

    Here is why Creative Realities Inc. (CREX) stock skyrocketed in the after-hours on Friday?

    Creative Realities Inc. (CREX) shares soared 25.34% in after-hours on Friday, November 12, 2021, and closed the weekly trading at $1.83. However, in the regular trading session of Friday, CREX’s stock lost 2.01%. CREX shares have risen 41.75% over the last 12 months, and they have moved down 7.01% in the past week. Over the past three months, the stock has lost 9.60%, while over the past six months, it has jumped 21.67%.

    Let’s have a look at its recent news and developments.

    CREX and Reflect Merger

    On November 12, 2021, Creative Realities, Inc. (CREX) and Reflect Systems, Inc. (Reflect) announced that the companies have executed a definitive merger agreement. The combined company will operate under the Creative Realities, Inc. name and continue to be listed on NASDAQ as CREX.

    Rick Mills, CRI’s CEO, who will continue to act as CEO for the combined company, said that this is an ideal combination.

    CREX upcoming financial results announcement

    Creative Realities, Inc. (CREXW) will release its financial results for the three and nine months ended on September 30, 2021, after the market closes on Monday, November 15, 2021.

    CREX Q2 financial results

    On August 16, 2021, Creative Realities, Inc. (CREX, CREXW), announced its financial results for the three- and six months ended June 30, 2021.

    Q2 2021 financial highlights

    • CREX reported total revenue of $3.3 million in Q2 2021 compared to $2.9 million in Q2 2020.
    • It earned a net income of $1.0 million in Q2 2021compared to a net loss of $2.5 million in 2020.
    • EBITDA was $1.9 million in Q2 2021 compared to an EBITDA loss of $1.7 million in Q2 2020.
    • Adjusted EBITDA was $0.3 million in Q2 2021, compared to an Adjusted EBITDA loss of $1.1 million in Q2 2020.

    Conclusion

    The recent merger announcement was the reason behind its massive surge in the after-hours on Friday and we expect it to continue its momentum after the weekend as well.

  • Why did Acutus Medical Inc. (AFIB) stock slump on Thursday?

    Acutus Medical Inc. (AFIB) shares declined 20.42% in after-hours on Thursday, November 11, 2021, and closed the daily trading at $5.30.  Even in the regular trading session, AFIB’s stock lost 9.88%. AFIB shares have fallen 72.65% over the last 12 months, and they have moved down 12.83% in the past week. Over the past three months, the stock has lost 42.39%, while over the past six months, it has slid down 51.21%.

    Let’s see is there any recent news behind its poor performance on Thursday?

    AFIB initiated AcQForce PFA-CE study

    On November 11, 2021, Acutus Medical, Inc. (AFIB) initiated AcQForce PFA-CE, a new clinical study that will evaluate the safety and performance of the company’s focal force-sensing Pulsed Field Ablation (PFA) catheter and system in combination with its novel noncontact 3D mapping system in treating patients with atrial fibrillation. The first patients were successfully treated at Na Homolce Hospital in the Czech Republic by Dr Petr Neuzil.

    AFIB latest financial results

    On November 11, 2021, Acutus Medical, Inc (AFIB) reported results for the third quarter of 2021.

    Q3 2021 financial highlights

    • AFIB earned total revenue of $4.6 million for the third quarter of 2021, compared to $3.2 million in the third quarter last year.
    • The cost of revenue was $8.5 million compared to $5.14 million in Q3 2020.
    • Total GAAP operating expenses were $23.2 million in Q3 2021 compared to $24.3 million in Q3 2020.
    • It suffered a GAAP net loss of $28.5 million or net loss per share of $0.94 for the third quarter of 2021 compared to a net loss of $31.2 million or a net loss per share of $1.95 in Q3 2020.
    • As of September 30, 2021, the company had cash, cash equivalents, marketable securities and restricted cash of $134.7 million.

    AFIB new appointment

    On August 12, 2021, Acutus Medical (AFIB), appointed Niamh Pellegrini to the Company’s Board of Directors.

    Ms Pellegrini has over 20 years of experience in the healthcare industry and, recently served as the Chief Commercial Officer of Nevro, Inc., since July 2019. Ms Pellegrini earned both a B.S. and an M.B.A. from Santa Clara University and she held positions in leadership, global business development, marketing, strategy and commercial with Thoratec Corporation and Johnson & Johnson.

    Conclusion

    The AFIB stock went down because of its poor Q3 financial performance. Though we had another positive news that did not stop its plummeting on Thursday. We can see it further decline on Friday as well.

  • Why AEye Inc. (LIDR) stock plunge in the after-hours on Thursday?

    Why AEye Inc. (LIDR) stock plunge in the after-hours on Thursday?

    AEye Inc. (LIDR) shares plunged 12.58% in after-hours on Thursday, November 11, 2021, and closed the daily trading at $5.70. However, in the regular trading session, LIDR’s stock gained 5.50%. LIDR shares have moved up 32.25% in the past week. Over the past three months, the stock has lost 26.33%, while over the past six months, it has declined 34.67%. The company has a current market of $1.08 billion and its outstanding shares stood at 29.25 million.

    Let’s have a look at its latest news and developments

    LIDR latest financial results

    On November 11, 2021, AEye, Inc. (LIDR), released its third-quarter 2021 financial results.

    Q3 2021 financial highlights

    • LIDR reported revenue of $0.1 million for Q3 2021 compared to $1.14 million for Q3 2020.
    • The cost of revenue was $0.5 million in Q3 2021 compared to $0.32 million in Q3 2020.
    • Total operating expenses were $16.54 million compared to $5.6 million in Q3 2020.
    • It suffered a GAAP net loss of $17.4 million, or $0.15 per share in Q3 2021 compared to a net loss of $3.8 million or $0.04 per share in Q3 2020.
    • Adjusted EBITDA was $12.5 million for the third quarter of 2021 compared to $4.3 million in Q3 2020.
    • As of September 30, 2021, the company had $182.4 million in cash and cash equivalents, and marketable securities and is debt-free.

    LIDR new appointment

    On November 11, 2021, AEye, Inc. (LIDR), appointed Dr T.R. Ramachandran as chief product officer. Ramachandran has more than two decades of experience delivering complex, market-leading solutions to large global customers. He will report to AEye CEO Blair LaCorte.

    LIDR won CES 2022 Innovation Award

    On November 11, 2021, AEye (LIDR) high-performance, adaptive LiDAR sensor, the 4Sight™ M, won a CES® 2022 Innovation award. The prestigious CES Innovation Awards honour outstanding design and engineering in consumer technology products and are given in advance of CES 2022.

    LIDR and Seoul Robotics technology integration

    On October 07, 2021, AEye, Inc. (LIDR), and Seoul Robotics announced the integration of AEye’s 4Sight M™ LiDAR sensor and Intelligent Detection and Ranging (iDAR™) software platform with Seoul Robotics’ SENSR™3D perception software. The integration will deliver a complete solution for long-range object detection, classification, and perception for Intelligent Traffic Systems (ITS) by providing best-in-class 3D perception for vehicles, cyclists, and pedestrians at distances beyond 300 meters.

    Conclusion

    The recent unimpressive Q3 results were the reason behind its loss in the after-market session on Thursday. let’s see how it perform on the last trading day of the week?